Skip to content

Exploring the scope of 4sb and 12a lymphadenectomy for advanced lower third gastric cancer: A study protocol for a prospective cohort trial

Exploring the scope of 4sb and 12a lymphadenectomy for advanced lower third gastric cancer: A study protocol for a prospective cohort trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057698
Enrollment
Unknown
Registered
2022-03-15
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Experiment group:New range of 12a and 4sb lymph node dissection
control:Traditional range of 12a and 4sb lymph node dissection

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The pathological diagnosis of gastroscopic biopsy was gastric cancer. The clinical staging of endoscopic ultrasonography or abdominal enhanced CT (CT) was cT2-4N0-3M0, and the tumor was located in the lower third of the stomach; 2. Complete laparoscopic distal gastrectomy D2 lymph node dissection; 3. Age 18-75, regardless of gender; 4. It can tolerate the cardiopulmonary function of radical gastrectomy; 5. Abide by the research protocol and sign the informed consent form; 6. Complete case information.

Exclusion criteria

Exclusion criteria: 1. If distant metastasis is found before or during operation, radical gastrectomy cannot be performed; 2. Those who cannot tolerate anesthesia or surgery or refuse surgery; 3. Cerebrovascular injury or serious heart disease occurred in recent 6 months; 4. Epilepsy history, central nervous system disease or mental disease history, hindering research cooperation; 5. Other diseases that seriously affect the survival time; 6. Organ transplantation requiring immunosuppressive therapy; 7. Pregnancy or lactation; 8. Participate in other clinical studies.

Design outcomes

Primary

MeasureTime frame
the 12a lymph nodes metastasis rate;

Secondary

MeasureTime frame
the 4sb lymph nodes metastasis rate;

Countries

China

Contacts

Public ContactZhang Jun

Beijing Friendship Hospital affiliated to Capital Medical University

zhangjun5986@ccmu.edu.cn+86 13811055986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026